Literature DB >> 19208897

Expression and Purification of glutathione transferase-small ubiquitin-related modifier-metallothionein fusion protein and its neuronal and hepatic protection against D-galactose-induced oxidative damage in mouse model.

Yadong Huang1, Zhijian Su, Yanmei Li, Qihao Zhang, Lejia Cui, Ye Su, Changcai Ding, Minjing Zhang, Chengli Feng, Yi Tan, Wenke Feng, Xiaokun Li, Lu Cai.   

Abstract

The present study aimed to produce and pathophysiologically evaluate the metallothionein (MT) fusion protein. A recombinant plasmid containing DNA segment coding the pET-glutathione transferase (GST)-small ubiquitin-related modifier (SUMO)-MT fusion protein was inserted into Escherichia coli for expression. The expression level of the fusion protein was very high, reaching to 38.4% of the total supernatant proteins from the organism. Subsequent filtration through glutathione Sepharose 4B gel and Sephadex G-25 yielded an MT fusion protein with purity more than 95%. When exposed to metals, E. coli containing the GST-SUMO-MT fusion protein showed an increased accumulation of Cd(2+), Zn(2+), or Cu(2+) at approximately 4.2, 4.0, or 1.6 times higher, respectively, than those containing the control protein. Administration of GST-SUMO-MT to mice that were also treated with D-galactose to induce neuronal and hepatic damage showed a significant improvement of animal learning and memory capacity, which was depressed in mice treated by D-galactose alone. Administration of MT fusion protein also prevented D-galactose-increased malondialdehyde contents and histopathological changes in the brain and liver. Furthermore, supplement of the fusion protein significantly prevented D-galactose-increased nitric oxide contents and -decreased superoxide dismutase activity in the brain, liver, and serum. The fusion protein was also able to prevent ionizing radiation-induced DNA damage of the mouse thymus. The present study indicates that GST-SUMO-MT has a normal metal binding feature and also significantly protects the multiple tissues against oxidative damage in vivo caused by chronic exposure to D-galactose and by ionizing radiation. Therefore, GST-SUMO-MT may be a potential candidate to be developed for the clinical application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208897     DOI: 10.1124/jpet.108.149401

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  D-Galactose High-Dose Administration Failed to Induce Accelerated Aging Changes in Neurogenesis, Anxiety, and Spatial Memory on Young Male Wistar Rats.

Authors:  Armando Cardoso; Sara Magano; Francisco Marrana; José P Andrade
Journal:  Rejuvenation Res       Date:  2015-08-20       Impact factor: 4.663

2.  D-galactose effectiveness in modeling aging and therapeutic antioxidant treatment in mice.

Authors:  Kodeeswaran Parameshwaran; Michael H Irwin; Kosta Steliou; Carl A Pinkert
Journal:  Rejuvenation Res       Date:  2011-01-04       Impact factor: 4.663

3.  High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli.

Authors:  Huiyan Wang; Yechen Xiao; Lianjun Fu; Hongxin Zhao; Yaofang Zhang; Xiaoshan Wan; Yuxia Qin; Yadong Huang; Hongchang Gao; Xiaokun Li
Journal:  BMC Biotechnol       Date:  2010-02-17       Impact factor: 2.563

4.  Prevention of gastrointestinal lead poisoning using recombinant Lactococcus lactis expressing human metallothionein-I fusion protein.

Authors:  Xue Xiao; Changbin Zhang; Dajun Liu; Weibin Bai; Qihao Zhang; Qi Xiang; Yadong Huang; Zhijian Su
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.